. 2011 Sep 3;23(1):327–337. doi: 10.1007/s00198-011-1755-2

Table 3.

Incidence of serious adverse events of skin infection

	Placebo (N = 3,876)^a, n (%)	Denosumab (N = 3,886)^a, n (%)
Serious adverse events of infection involving the skin	3 (<0.1)	15 (0.4)*
Cellulitis and erysipelas	1 (<0.1)	12 (0.3)^b
Skin bacterial infection	0 (0)	2 (<0.1)
Staphylococcal infection	1 (<0.1)	1 (<0.1)
Infected skin ulcer	0 (0)	1 (<0.1)^b
Subcutaneous abscess	1 (<0.1)	0 (0)

*P < 0.05 vs placebo

^aNumber of subjects who received ≥1 dose of investigational product

^bOne subject in the denosumab group experienced events of cellulitis and erysipelas and infected skin ulcer